Graves’ Disease Market, By Disease Type (Overt Graves’ Disease and Subclinical Graves’ Disease), By Symptom (Thyrotoxicosis, Graves Orbitopathy (Ocular), Dermopathy (Pretibial Myxedema), and Other Systemic Manifestations), By Diagnostic Method (Clinical Evaluation, Imaging (Ultrasound, Radioiodine Uptake Scan, MRI/CT (for orbitopathy)), and Laboratory (TSH, Free T3/Free T4, TSH Receptor Antibodies (TRAb))), By Treatment Modality (Pharmacological (Antithyroid Drugs (Methimazole, Propylthiouracil, and Carbimazole), Beta‑Blockers, Corticosteroids, Immunosuppressants), Radioactive Iodine Therapy, Surgical (Total Thyroidectomy and Subtotal Thyroidectomy), Adjunctive/Ocular(Orbital Decompression, Rituximab, and Teprotumumab), and Supportive/Other (Lifestyle/Adjunctive Care)), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Home Care Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2026-2033)